{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-146584","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2023-05-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.551091+00:00","generated_at":"2026-06-14T22:32:24.268849+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"TScan reports preliminary Phase 1 data for TSC-100/101; TSC-101 advances to Dose Level 2","bullets":["TSC-101 in high-risk MDS patient: 100% donor chimerism, no p53 mutation detected (sensitivity 0.01%), no DLTs.","TSC-100 in T-cell ALL patient showed T cell expansion with activation markers on Day 7 post-infusion.","Study advancing TSC-101 to Dose Level 2; RP2D and interim data expected by end of 2023.","Two control patients with MDS had incomplete donor chimerism; one in early relapse.","Phase 1 trial design includes three dose levels; second dose at DL2 and DL3 for both candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-146584","json":"https://secwatch.observer/filing/0001193125-23-146584.json","markdown":"https://secwatch.observer/filing/0001193125-23-146584.md","text":"https://secwatch.observer/filing/0001193125-23-146584.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523146584/0001193125-23-146584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523146584/d490821d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T22:32:24.268849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}